De Novo and Secondary Myelodysplastic Syndromes
Treatment of de novo and secondary myelodysplastic syndromes may include the following:
- Supportive care with transfusion therapy
- High-dose chemotherapy with stem cell transplant using stem cells from a donor
- Supportive care with growth factor therapy
- Chemotherapy with azacitidine, decitabine, or other anticancer drugs
- Supportive care with drug therapy
- A clinical trial of a new anticancer drug
- A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor
- A clinical trial of a combination of treatments
- A clinical trial of growth factor therapy
Previously Treated Myelodysplastic Syndromes
Treatment of previously treated myelodysplastic syndromes may include the following:
- High-dose chemotherapy with stem cell transplant using stem cells from a donor
- Chemotherapy with azacitidine or decitabine
- Supportive care with transfusion therapy, growth factor therapy, and/or drug therapy
- A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor
- A clinical trial of new drug therapy
- A clinical trial of a combination of treatments
- A clinical trial of growth factor therapy